In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
Open Access
- 9 April 2018
- journal article
- research article
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 28 (5), 654-665
- https://doi.org/10.1101/gr.230219.117
Abstract
Cisplatin reacts with DNA and thereby likely generates a characteristic pattern of somatic mutations, called a mutational signature. Despite widespread use of cisplatin in cancer treatment and its role in contributing to secondary malignancies, its mutational signature has not been delineated. We hypothesize that cisplatin's mutational signature can serve as a biomarker to identify cisplatin mutagenesis in suspected secondary malignancies. Knowledge of which tissues are at risk of developing cisplatin-induced secondary malignancies could lead to guidelines for noninvasive monitoring for secondary malignancies after cisplatin chemotherapy. We performed whole genome sequencing of 10 independent clones of cisplatin-exposed MCF-10A and HepG2 cells and delineated the patterns of single and dinucleotide mutations in terms of flanking sequence, transcription strand bias, and other characteristics. We used the mSigAct signature presence test and nonnegative matrix factorization to search for cisplatin mutagenesis in hepatocellular carcinomas and esophageal adenocarcinomas. All clones showed highly consistent patterns of single and dinucleotide substitutions. The proportion of dinucleotide substitutions was high: 8.1% of single nucleotide substitutions were part of dinucleotide substitutions, presumably due to cisplatin's propensity to form intra- and interstrand crosslinks between purine bases in DNA. We identified likely cisplatin exposure in nine hepatocellular carcinomas and three esophageal adenocarcinomas. All hepatocellular carcinomas for which clinical data were available and all esophageal cancers indeed had histories of cisplatin treatment. We experimentally delineated the single and dinucleotide mutational signature of cisplatin. This signature enabled us to detect previous cisplatin exposure in human hepatocellular carcinomas and esophageal adenocarcinomas with high confidence.Funding Information
- NMRC (CIRG/1422/2015)
This publication has 54 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaGenome Research, 2013
- Deciphering Signatures of Mutational Processes Operative in Human CancerCell Reports, 2013
- Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesisNucleic Acids Research, 2012
- Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairsBioinformatics, 2012
- Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantationLiver Transplantation, 2011
- International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics dataDatabase: The Journal of Biological Databases and Curation, 2011
- The NIH Roadmap Epigenomics Mapping ConsortiumNature Biotechnology, 2010
- Quantile smoothing of array CGH dataBioinformatics, 2004
- Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II)Biochemistry, 1983